You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 雅各臣科研製藥(2633.HK)漲超7% 擬分拆健倍苗苗(保健)於港交所主板上市
格隆匯 09-24 09:45
格隆匯9月24日丨雅各臣科研製藥(2633.HK)高開高走,現漲超7%,報1.22港元,總市值23.6億港元。雅各臣科研製藥昨日公告,公司建議分拆集團的品牌醫療保健業務於聯交所主板獨立上市,方式為將公司附屬公司健倍苗苗的部分股份實物分派予合資格股東,以及於香港公開發售新的健倍苗苗股份。於公告日期,公司間接持有健倍苗苗股份的85.04%,目前預期於建議分拆完成後,公司將持有健倍苗苗不少於50%權益,而健倍苗苗將繼續為公司的附屬公司。分拆集團主要從事製造及買賣品牌醫療保健品,包括消費者醫療保健品及品牌中藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account